Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1648 1652 1671 1672
This examiner grants 68% of resolved cases
Agnieszka Boesen is an examiner in Tech Center 1600, specifically working within Art Unit 1632. She has 842 resolved cases, which provides a reliable sample of her examination history. The allowance rate pct for Boesen is 68.5, indicating that a majority of the applications she reviews result in a grant. This 68.5 allowance rate pct suggests a favorable environment for applicants in Art Unit 1632.
The interview lift pct of 21.8 is a significant factor for practitioners to consider. This value indicates that conducting an interview with Boesen notably increases the probability of allowance. The median days to allowance is 1169, showing the typical timeline for successful cases. Given the 21.8 interview lift pct and the 1169 median days to allowance, interviews appear to be a valuable tool for resolving issues and reaching a conclusion. With 842 resolved cases, Boesen's profile suggests that active engagement can help navigate the prosecution process in Tech Center 1600 effectively.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18280362 | VLP ENTEROVIRAL VACCINES | Non-Final OA | ModernaTX, Inc. |
| 18260110 | HERPES SIMPLEX VIRUS TYPE 1 DERIVED INFLUENZA VACCINE | Non-Final OA | The Regents of the University of California |
| 18283042 | Highly Attenuated Replication-Competent Recombinant Poxvirus As A Vaccine Platform And Methods Of Use | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 18723259 | STABILISED LIQUID VACCINES OF LIVE VIRUSES | Non-Final OA | INTERVET INC. |
| 18702577 | A VACCINE FOR THE PROTECTION OF PIGLETS AGAINST SWINE INFLUENZA A VIRUS INFECTION | Non-Final OA | Intervet Inc. |
| 18723099 | METHODS FOR DETECTING OR TREATING INFLUENZA INFECTIONS | Non-Final OA | THE UNIVERSITY OF CHICAGO |
| 18750780 | ANTI-CAR COMPOSITIONS AND METHODS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18687763 | IMMUNOFOCUS ASSAY FOR DETERMINING THE TITER OF DENGUE VIRUSES | Non-Final OA | TAKEDA VACCINES, INC. |
| 18667046 | RSV IMMUNIZATION REGIMEN | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18259893 | NOROVIRUS VIRUS-LIKE PARTICLE, IMMUNE COMPOSITION, OR KIT, AND USE THEREOF | Final Rejection | GRAND THERAVAC LIFE SCIENCE (NANJING) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy